the do tirofiban and reoprogive similar efficacy outcome trial (TARGET) associated withimproved outcomes including one-year survival: Results from Triple antiplatelet therapy during percutaneous coronary intervention is
msra
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要